Genentech cites "encouraging"pertuzumab data

Genentech announced that its experimental ovarian cancer drug pertuzumab "encouraging" data in a mid-stage trial, but one news report quoted an analyst who claimed the company had confirmed that the trial had not produced statistically significant results. The full range of data will be presented at an upcoming medical gathering. The study collected data on 130 women with advanced ovarian cancer. A news service quoted analyst Jason Kantor who reportedly confirmed that while the data was 'encouraging,' the study did not meet its primary endpoint.

- check out Genentech's press release
- here's the AP report for more

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.